朱蘭英
【摘 要】目的:研究慢性阻塞性肺氣腫疾病采用噻托溴銨粉霧劑進(jìn)行治療的臨床效果。方法:選擇76例慢性阻塞性肺氣腫疾病患者,分成對(duì)照組和治療組,平均每組38例。對(duì)照組采用氨茶堿進(jìn)行治療;治療組采用噻托溴銨粉霧劑進(jìn)行治療。結(jié)果:治療組患者肺氣腫治療總有效率為91.4%,對(duì)照組為70.7%(P<0.05);肺功能指標(biāo)治療前后水平改善幅度大于對(duì)照組(P<0.05);藥物不良反應(yīng)僅有1例,少于對(duì)照組的7例(P<0.05);癥狀消失時(shí)間、肺功能指標(biāo)復(fù)常時(shí)間、治療總時(shí)間短于對(duì)照組(P<0.05)。結(jié)論:慢性阻塞性肺氣腫疾病采用噻托溴銨粉霧劑進(jìn)行治療,能夠縮短癥狀控制時(shí)間和用藥時(shí)間,大幅度改善肺部功能的同時(shí)有效控制不良反應(yīng),使治療的總有效率得以提升。
【關(guān)鍵詞】慢性阻塞性肺氣腫;噻托溴銨粉霧劑;治療
Abstract Objective: To study the clinical effect of Tiotropium Bromide Powder for Inhalation for the treatment of chronic obstructive emphysema.Methods: 76 patients with chronic obstructive emphysema were selected and divided into the control group and the treatment group, with an average of 38 cases in each group.The control group was treated with aminophylline, and the treatment group was treated with Tiotropium Bromide Powder for Inhalation.Results: the treatment group patients with emphysema treatment the total effective rate was 91.4%, 70.7% in the control group (P < 0.05); pulmonary function index before and after treatment to improve the level of higher than those of the control group (P < 0.05); 1 cases with adverse drug reaction, less than 7 cases in the control group (P < 0.05); the symptoms disappear time function lung, recovery time and total treatment time was shorter than the control group (P < 0.05).Conclusion: chronic obstructive pulmonary emphysema disease treated by Tiotropium Bromide Powder for Inhalation can shorten symptom control time and medication time, improve lung function and control adverse reactions, so that the total effective rate of treatment can be improved.
Key words: Chronic obstructive emphysema; Tiotropium Bromide Powder for Inhalation; treatment
【中圖分類號(hào)】R643.1 【文獻(xiàn)標(biāo)識(shí)碼】A 【文章編號(hào)】1672-3783(2018)02-03-0-01
慢性阻塞性肺氣腫近年來已經(jīng)成為我國(guó)臨床呼吸內(nèi)科中發(fā)病率水平較高的一種疾病,導(dǎo)致其發(fā)病的實(shí)質(zhì)性原因是患者機(jī)體呼吸細(xì)支氣管遠(yuǎn)端末梢位置的肺組織由于殘氣量異常增多而長(zhǎng)時(shí)間的處于一種擴(kuò)張狀態(tài)下,并對(duì)肺泡間隔造成一定的破壞,使得肺組織的彈性水平明顯減弱,容積異常增大,呼吸困難是該病患者的臨床特征表現(xiàn),在發(fā)病之后生活質(zhì)量會(huì)受到嚴(yán)重的不良影響[1]。本文研究慢性阻塞性肺氣腫疾病采用噻托溴銨粉霧劑進(jìn)行治療的臨床效果?,F(xiàn)就研究的過程及結(jié)果做如下內(nèi)容的匯報(bào)。
1 資料和方法
1.1 一般資料
抽取2015年10月-2017年10月在我院接受治療的76例慢性阻塞性肺氣腫疾病患者,通過隨機(jī)分組的方式,將其分成對(duì)照組和治療組,平均每組38例。對(duì)照組中男性22例,女性16例;年齡53-88歲,平均(64.9±5.6)歲;慢性阻塞性肺氣腫病史1-19年,平均(5.1±0.5)年;本次發(fā)病時(shí)間1-14小時(shí),平均(5.7±1.2)小時(shí);治療組中男性25例,女性13例;年齡51-84歲,平均(64.3±5.9)歲;慢性阻塞性肺氣腫病史1-16年,平均(5.4±0.9)年;本次發(fā)病時(shí)間1-18小時(shí),平均(5.2±1.6)小時(shí)。上述自然資料數(shù)據(jù),兩組組間比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),所得數(shù)據(jù)可以進(jìn)行科學(xué)比較分析。
1.2 方法
對(duì)照組:口服氨茶堿,每次200mg,每天用藥兩次,連續(xù)用藥治療兩個(gè)月;治療組:霧化吸入噻托溴銨粉霧劑,每次18μg,每天用藥一次,連續(xù)用藥治療兩個(gè)月。
1.3 觀察指標(biāo)
(1)肺氣腫治療總有效率;(2)肺功能指標(biāo)治療前后水平;(3)藥物不良反應(yīng);(4)癥狀消失時(shí)間、肺功能指標(biāo)復(fù)常時(shí)間、治療總時(shí)間。